BCLI — Brainstorm Cell Therapeutics Share Price
0.000.00%
Last trade - 00:00- $8.22m
- $8.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Directors
- Jacob Frenkel CHM (77)
- Ralph Kern PRE (63)
- Chaim Lebovits CEO (50)
- Irit Arbel VCH (61)
- Alla Patlis CFO (34)
- David Setboun COO (46)
- Uri Yablonka EVP (44)
- Stacy Lindborg EVP (50)
- Anthony Waclawski EVP (50)
- Arturo Araya OTH (50)
- Menghisteab Bairu DRC (60)
- June Almenoff IND (65)
- Anthony Polverino IND (58)
- Malcolm Taub IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 15th, 2006
- Public Since
- May 28th, 2003
- No. of Shareholders
- 29
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,522,350
- Address
- 1325 Avenue Of Americas, 28Th Floor, NEW YORK, 10019
- Web
- https://brainstorm-cell.com/
- Phone
- +1 2014880460
- Auditors
- Brightman Almagor Zohar & Co
Upcoming Events for BCLI
Q2 2025 Brainstorm Cell Therapeutics Inc Earnings Release
Brainstorm Cell Therapeutics Inc Annual Shareholders Meeting
Similar to BCLI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Brainstorm Cell Therapeutics share price?
As of Today at 19:41 UTC, shares in Brainstorm Cell Therapeutics are trading at $1.26. This share price information is delayed by 15 minutes.
How has the Brainstorm Cell Therapeutics share price performed this year?
Shares in Brainstorm Cell Therapeutics last closed at $1.26 and the price had moved by -78.91% over the past 365 days. In terms of relative price strength the Brainstorm Cell Therapeutics share price has underperformed the S&P500 Index by -80.98% over the past year.
What are the analyst and broker recommendations for Brainstorm Cell Therapeutics?
The overall consensus recommendation for Brainstorm Cell Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Brainstorm Cell Therapeutics dividend yield?
Brainstorm Cell Therapeutics does not currently pay a dividend.
Does Brainstorm Cell Therapeutics pay a dividend?
Brainstorm Cell Therapeutics does not currently pay a dividend.
When does Brainstorm Cell Therapeutics next pay dividends?
Brainstorm Cell Therapeutics does not currently pay a dividend.
How do I buy Brainstorm Cell Therapeutics shares?
To buy shares in Brainstorm Cell Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Brainstorm Cell Therapeutics?
As of the previous close price of $1.26, shares in Brainstorm Cell Therapeutics had a market capitalisation of $8.22m.
Where are Brainstorm Cell Therapeutics shares listed?
Here are the trading details for Brainstorm Cell Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BCLI
What kind of share is Brainstorm Cell Therapeutics?
Based on an overall assessment of its quality, value and momentum Brainstorm Cell Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Brainstorm Cell Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Brainstorm Cell Therapeutics is $12.50. That is 892.06% above the last closing price of $1.26.
Analysts covering Brainstorm Cell Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.91 for the next financial year.
Find out moreWhat is the trend in the Brainstorm Cell Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Brainstorm Cell Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -31.95%.
As of the last closing price of $1.26, shares in Brainstorm Cell Therapeutics were trading -48.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Brainstorm Cell Therapeutics PE Ratio?
The Brainstorm Cell Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics' management team is headed by:
- Jacob Frenkel - CHM
- Ralph Kern - PRE
- Chaim Lebovits - CEO
- Irit Arbel - VCH
- Alla Patlis - CFO
- David Setboun - COO
- Uri Yablonka - EVP
- Stacy Lindborg - EVP
- Anthony Waclawski - EVP
- Arturo Araya - OTH
- Menghisteab Bairu - DRC
- June Almenoff - IND
- Anthony Polverino - IND
- Malcolm Taub - IND